Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

被引：0

作者：

Kan Yonemori

Kenji Tamura

Makoto Kodaira

Koshi Fujikawa

Tamotsu Sagawa

Taito Esaki

Tsuyoshi Shirakawa

Fumihiko Hirai

Yuki Yokoi

Toshio Kawata

Ben Hatano

Yasuo Takahashi

机构：

[1] National Cancer Center Hospital,Department of Breast and Medical Oncology

[2] National Hospital Organization Hokkaido Cancer Center,Department of Gastroenterology

[3] National Hospital Organization Kyushu Cancer Center,Department of Gastrointestinal and Medical Oncology

[4] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology

[5] AstraZeneca R and D,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2016年 / 78卷

关键词：

Olaparib; Poly(ADP-ribose) polymerase inhibitors; Clinical trial, Phase I; Safety; Solid tumours;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：525 / 531

页数：6

共 169 条